血清降钙素原对急性呼吸困难患者肺炎的诊断准确性:系统评价与Meta分析
该系统评价纳入6项研究共2341例患者(576例肺炎,1765例无肺炎),评估血清降钙素原对急性呼吸困难患者肺炎的诊断准确性。合并敏感度0.67(95%CI 0.58-0.75),特异度0.76(95%CI 0.67-0.83),sROC曲线下面积0.77(95%CI 0.73-0.80)。阳性似然比2.8(95%CI 2.0-3.8),阴性似然比0.44(95%CI 0.34-0.56),诊断比值比6(95%CI 4-10)。结论认为血清降钙素原仅具有中等诊断价值,单独使用不足以确认或排除肺炎。
要点
- 在急性呼吸困难患者中,血清降钙素原诊断肺炎的合并敏感度为0.67(95%CI 0.58-0.75),特异度为0.76(95%CI 0.67-0.83)。
- sROC曲线下面积为0.77(95%CI 0.73-0.80),提示仅中等诊断准确性。
- 阳性似然比2.8(95%CI 2.0-3.8),阴性似然比0.44(95%CI 0.34-0.56),诊断比值比6(95%CI 4-10)。
- 纳入研究未显示显著发表偏倚。
- 血清降钙素原单独使用不足以确认或排除急性呼吸困难患者的肺炎。
适用人群与场景
- 急性呼吸困难患者,评估肺炎诊断准确性。
研究设计与关键结果
- 系统评价与Meta分析,纳入6项研究,共2341例患者(576例肺炎,1765例无肺炎)。
- 血清降钙素原诊断肺炎的合并敏感度0.67(95%CI 0.58-0.75),特异度0.76(95%CI 0.67-0.83)。
- sROC曲线下面积0.77(95%CI 0.73-0.80),阳性似然比2.8(95%CI 2.0-3.8),阴性似然比0.44(95%CI 0.34-0.56),诊断比值比6(95%CI 4-10)。
- 纳入研究未显示显著发表偏倚。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析。
- 纳入研究质量使用QUADAS-2评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 血清降钙素原对急性呼吸困难相关肺炎仅中等诊断价值,单独使用不足以确认或排除肺炎。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Several studies have investigated the diagnostic value of serum procalcitonin (PCT) for pneumonia in patients with acute dyspnea, but results have been inconsistent. This systematic review aimed to determine the diagnostic accuracy of serum PCT for pneumonia in patients with acute dyspnea.
METHODS: We searched the PubMed and Web of Science databases to identify studies evaluating the diagnostic accuracy of serum PCT for pneumonia-associated acute dyspnea published before October 1, 2025. The quality of the included studies was assessed using the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). We used a bivariate model to be pooled sensitivity and specificity. The overall diagnostic accuracy was evaluated using a summary receiver operating characteristic curve (sROC). Deek's test was used to assess publication bias.
RESULTS: We included 6 studies involving 2341 patients (576 with pneumonia and 1765 without). Serum PCT's pooled sensitivity and specificity for diagnosing pneumonia-related acute dyspnea were 0.67 (95% CI: 0.58-0.75) and 0.76 (95% CI: 0.67-0.83), respectively. The area under the sROC curve (AUC) was 0.77 (95% CI: 0.73-0.80). The positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 2.8 (95% CI: 2.0-3.8) and 0.44 (95% CI: 0.34-0.56), respectively. The diagnostic odds ratio (DOR) was 6 (95% CI: 4-10). The included studies showed no significant publication bias.
CONCLUSIONS: Serum PCT has only moderate diagnostic value for pneumonia-related acute dyspnea and is insufficient to confirm or exclude pneumonia when used alone.
参考来源
- Am J Emerg Med:Diagnostic accuracy of serum procalcitonin for pneumonia in patients with acute dyspnea: a systematic review and meta-analysis
- Cui JY, Wang HJ, Xu YN, et al. Diagnostic accuracy of serum procalcitonin for pneumonia in patients with acute dyspnea: a systematic review and meta-analysis. Am J Emerg Med. 2026. PMID: 42971102. doi:10.1016/j.ajem.2026.10.031
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。